Gastrointestinal Dysfunction in Aortic Surgery Patients

July 23, 2024 updated by: Gustavo Rojas Velasco, Instituto Nacional de Cardiologia Ignacio Chavez

Assessment of Gastrointestinal Dysfunction Through GIDS Scale and Intestinal Damage Biomarkers in Critically Ill Patients Undergoing Aortic Surgery and Its Association With Clinical Outcomes.

The goal of this observational study is to determine the association of gastrointestinal dysfunction through the Gastrointestinal Dysfunction Scale (GIDS) tool and serum concentrations of citrulline and Intestinal fatty-acid binding protein (I-FABP) with primary [calories received, protein received, parenteral nutrition requirement and 28-day mortality in the intensive care unit (ICU)] and secondary (development of pneumonia, surgical and cardiovascular complications in the ICU, length of hospital and ICU stay, duration of mechanical ventilation) clinical outcomes in critically ill patients undergoing aortic surgery.

Study Overview

Detailed Description

The treatment of choice for various cardiovascular diseases often involves cardiac surgery, including aortic surgery, which is performed to correct conditions related to this major vessel, such as aneurysms, stenosis, aortic dissections, as well as issues affecting the aortic valve. With the increasing prevalence of non-communicable chronic diseases, a 46% increase in demand for cardiac surgeries is projected by 2025. The post-surgical period, commonly in the intensive care unit (ICU), increases the risk of complications, especially in patients with pre-existing risk factors. In this regard, gastrointestinal (GI) dysfunction affects up to 63% of patients, being associated with complications and a mortality rate of 55% to 60%. Early detection of GI dysfunction allows for the implementation of management strategies. Additionally, the administration of appropriate nutritional therapy is essential for recovery, and GI dysfunction may limit nutrient absorption. Inadequate caloric intake has been linked to increased morbidity and mortality. Tools such as GIDS (Gastrointestinal Dysfunction Scale) and biomarkers like citrulline and I-FABP enable early evaluation of GI function, advancing monitoring and management. Identifying changes before serious complications arise allows for early and personalized interventions. Early detection not only prevents complications and improves quality of life but may also reduce mortality. This research project aims to address these gaps by early assessing GI dysfunction in post-aortic surgery patients. Utilizing the GIDS tool and biomarkers such as citrulline and I-FABP, the goal is to identify GI dysfunction early and its impact on nutrition administration.

Study Type

Observational

Enrollment (Estimated)

114

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Tlalpan
      • Ciudad de mexico, Tlalpan, Mexico, 14080
        • Recruiting
        • Instituto Nacional de Cardiologia Ignacio Chavez
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Jacob J Cruz Sánchez, MSc
        • Sub-Investigator:
          • Daniel Manzur Sandoval, MD
        • Sub-Investigator:
          • Carla G Aguilar Rodríguez, MD
        • Sub-Investigator:
          • Eduardo A Escudero González, MD
        • Sub-Investigator:
          • María L Tovar Hernández, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Adult patients following aortic surgery necessitating invasive mechanical ventilation and an intensive care unit stay of ≥ 48 hours.

Description

Inclusion Criteria:

  • 18 years of age or older.
  • Patients after surgical interventions (elective or urgency) on the aorta with cardiopulmonary bypass.
  • Invasive mechanical ventilation expected to be required more than 48 hours.
  • Signed informed consent.

Exclusion Criteria:

  • Patients under mechanical ventilation with pre-existing gastrointestinal issues.
  • Diagnosis of adult congenital heart disease.
  • Ongoing pregnancy or lactation period.
  • Simultaneous participation in another clinical study involving experimental therapy.
  • Presence of chronic intestinal disease.
  • Previous gastrointestinal conditions detected during nutritional screening.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Calories delivered daily enterally and/or parenterally
Time Frame: Day 0 to day 7
Percentage representation of prescribed calories delivered daily via enteral and/or parenteral routes.
Day 0 to day 7
Protein delivered daily enterally and/or parenterally
Time Frame: Day 0 to day 7
Daily administration of protein (in grams) through enteral and/or parenteral routes.
Day 0 to day 7

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence rate of hospital-acquired infections
Time Frame: 7 days
Infections acquired in the hospital consist of ventilator-associated pneumonia, bloodstream infections, and infections related to urinary catheters
7 days
Percentage of repeated operations
Time Frame: 90 days
This outcome measures the percentage of patients who undergo one or more additional surgical operations related to the same condition after the initial surgery. The percentage is calculated by dividing the number of patients who require a repeat operation by the total number of patients who underwent the initial operation, multiplied by 100 to get the percentage.
90 days
ICU readmission rate
Time Frame: 90 days
Occurrences of patients being readmitted to the ICU from within the hospital.
90 days
ICU length of stay
Time Frame: 90 days
Duration of time (days) in the ICU
90 days
Duration of mechanical ventilation
Time Frame: 90 days
Length of time (days) on mechanical ventilation (including still on mechanical ventilation at time of discharge)
90 days
Hospital length of stay
Time Frame: 90 days
Duration of time (days) in the hospital
90 days
Parenteral nutrition requirement
Time Frame: Day 0 to day 7
Parenteral nutrition requirement
Day 0 to day 7
28-day mortality in the ICU
Time Frame: 28 days
Is the patient alive or deceased 28 days post admission.
28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gustavo Rojas Velasco, MD, Head of the Cardiovascular Intensive Care Unit

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 23, 2024

Primary Completion (Estimated)

April 1, 2026

Study Completion (Estimated)

June 1, 2026

Study Registration Dates

First Submitted

July 9, 2024

First Submitted That Met QC Criteria

July 16, 2024

First Posted (Actual)

July 23, 2024

Study Record Updates

Last Update Posted (Actual)

July 24, 2024

Last Update Submitted That Met QC Criteria

July 23, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastrointestinal Dysfunction

Clinical Trials on No intervention

Subscribe